be if there are further delays to the Biomet deal, which has already been postponed ..... the full year thanks to the addition of Biomet , though we were pleased that management ..... revenue growth, especially because once the Biomet deal closes, management will have its
BRUSSELS, March 30 (Reuters) - U.S. medical device maker Zimmer gained European Union regulatory approval on Monday for its proposed $13.4 billion purchase of rival Biomet after agreeing to divest...
confident that its impending purchase of Biomet will close in the first quarter. We think ..... lines in order to make its purchase of Biomet pass muster with antitrust regulators ..... how the regulators handle the Zimmer- Biomet situation may be instructive for any peer
the med tech space, such as Becton Dickinson's acquisition of Carefusion for 3.1 times sales and Zimmer's purchase of Biomet for 4.2 times sales, provide some support to this deal. The Volcano acquisition is in line with Philips' strategy to become
Nonetheless, we still think greater pricing pressure is now a fixture in the post health-care reform world. We still expect the Biomet deal to close in first quarter of 2015, but would be very surprised if the antitrust regulators did not force Zimmer to make
its acquisition of midtier competitor Biomet . Antitrust regulators in Europe and the ..... will close, and we continue to include Biomet in our valuation. With quarterly revenue ..... its spine business with the addition of Biomet . There just is not enough high-quality
Blackstone's 8.4%, Carlyle's 5%, and the S&P 500's 4.7% increases. Upcoming sales transactions for US Foods and Biomet will generate more incentive income in the next quarter or two. With the completion of the KFN deal, KKR (at the asset manager
Biomet moves closer to private territory.
announcement that Zimmer ZMH plans to acquire Biomet , the competitive dynamics in the orthopedic ..... orthopedic surgeons. Zimmer's acquisition of Biomet removes one midtier competitor from the ..... Economic Moat Rating, and the addition of Biomet (which we had also rated as wide moat
Zimmer 's ZMH "> ZMH credit rating, which we cut to BBB+ from AA on its plan to purchase Biomet for $13.35 billion, including the assumption of Biomet 's $5.5 billion in net debt. Excluding synergies, Zimmer's debt/EBITDA will rise